Latigo Biotherapeutics, Inc.
LTGO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002056611
In the last 90 days, Latigo Biotherapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $2.52M in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LTGO, Q2 2026
No superinvestor reported holding LTGO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Latigo Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 (view filing)8:21 PM ET | Aug 10 | Same day | Foresite Capital Fund V, L.P. and 5 others10% Owner | PPurchase | +140.0K | $18.00 | +$2.52M | +7.5%2.01M after | Duplicate filing |
| Aug 10, 2026 (view filing)8:00 PM ET | Aug 10 | Same day | Tananbaum James B.Director, 10% Owner | PPurchase | +140.0K | $18.00 | +$2.52M | +7.5%2.01M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Latigo Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding LTGO in 13F filings for Q2 2026.